Overview

Full Product Details

Author:   Paul L. Herrling (Sandoz Research Institute, Berne, Switzerland)
Publisher:   Elsevier Science Publishing Co Inc
Imprint:   Academic Press Inc
Dimensions:   Width: 15.20cm , Height: 1.40cm , Length: 22.90cm
Weight:   0.510kg
ISBN:  

9780125468206

ISBN 10:   0125468202
Pages:   156
Publication Date:   10 January 1997
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Out of stock  
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.

Table of Contents

M. Schmutz, A. Arthur, H. Faleck, G. Karlsson, A. Kotake, L. Landwicki, L. LaRue, S. Markabi, D. Murphy, M. Powell, and D. Sauer, Selfotel. P. Herrling et al., D-CPPene (SDZ EAA-494) A Competitive NMDA Antagonist: Pharmacology and Results in Humans. J.D. Kristensen, Intrathecal Administration of a Competitive NMDA Receptor Antagonist for Pain Treatment. A.G. Knapp, L.I. Matthews, and E.R. Gamzu, Clinical Experience with the NMDA Ion-Channel Blocker, Aptiganel Hydrochloride (CEROSTAT). M.-L. Maccecchini, Development of ACPC: A Partial Agonist of the Glycine Site on the NMDA Receptor. Carter et al., Ifenprodil and Eliprodil: Neuroprotective NMDA Receptor Antagonists and Calcium Channel Blockers. D. Lodge and D.D. Schoepp, 3S, 8aR-6-[2-(1(2)H-tetrazole-5-y)ethyl] Decahydroisoquinoline-3-carboxylic Acid (LY293558) and Its Racemate (LY215490): A Selective and Competitive AMPA/Kainate Receptor Agonist. L. Nordholm, M. Sheardown, and T. Honore, The NBQX Story. E. Louvel, Riluzole in Amytrophic Lateral Sclerosis. G.C. Plamer and J.B. Hutchinson, Preclinical and Clinical Aspects of Remacemide Hydrochloride.

Reviews

"""This book is intended for research neuroscientists but can be effectively utilized by clinicians and students because of its clarity of style and excellent illustrations... Many excellent diagrams and charts are scattered throughout this volume. They make for easy conceptualization of the results of preclinical as well as phase one and two clinical trials... This book provides a much needed report on these exciting neuroprotective agents, several of which will be released by the FDA in the near future."" --Thomas H. Jobe, MD, University of Illinois at Chicago College of Medicine for DOODY'S PUBLISHING REVIEWS"

This book is intended for research neuroscientists but can be effectively utilized by clinicians and students because of its clarity of style and excellent illustrations... Many excellent diagrams and charts are scattered throughout this volume. They make for easy conceptualization of the results of preclinical as well as phase one and two clinical trials... This book provides a much needed report on these exciting neuroprotective agents, several of which will be released by the FDA in the near future. --Thomas H. Jobe, MD, University of Illinois at Chicago College of Medicine for DOODY'S PUBLISHING REVIEWS

Author Information

Paul L. Herrling is currently Head of Corporate Research at Sandoz Pharmacies in Basel, Switzerland.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions